Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for PRTA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -15.50M
March 31, 2026 -6.946M
December 31, 2025 0.0021M
September 30, 2025 -0.0188M
June 30, 2025 -0.0786M
March 31, 2025 -0.048M
December 31, 2024 -0.098M
September 30, 2024 0.355M
June 30, 2024 0.4389M
March 31, 2024 0.836M
December 31, 2023 -0.0547M
September 30, 2023 2.710M
June 30, 2023 18.93M
March 31, 2023 23.28M
December 31, 2022 214.86M
September 30, 2022 17.00M
June 30, 2022 1.159M
March 31, 2022 1.337M
December 31, 2021 -1.466M
September 30, 2021 83.93M
June 30, 2021 20.27M
March 31, 2021 81.33M
December 31, 2020 0.0009M
September 30, 2020 0.0729M
June 30, 2020 0.00
Date Value
March 31, 2020 0.151M
December 31, 2019 0.013M
September 30, 2019 -0.0014M
June 30, 2019 0.2089M
March 31, 2019 0.005M
December 31, 2018 -1.602M
September 30, 2018 -1.343M
June 30, 2018 -1.507M
March 31, 2018 43.18M
December 31, 2017 -1.406M
September 30, 2017 10.03M
June 30, 2017 4.158M
March 31, 2017 159.87M
December 31, 2016 15.15M
September 30, 2016 3.587M
June 30, 2016 2.532M
March 31, 2016 129.06M
December 31, 2015 3.263M
September 30, 2015 2.088M
June 30, 2015 132.64M
March 31, 2015 1.026M
December 31, 2014 -4.16M
September 30, 2014 11.90M
June 30, 2014 102.96M
March 31, 2014 0.507M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Alkermes Plc 17.20M
Amarin Corp. Plc -0.2495M
Agenus, Inc. 14.68M
Amgen, Inc. -1.482B
Anika Therapeutics, Inc. -0.701M